This is great news.
Perhaps it was their plan all along (until COVID came along) to start with development of treatments for external (skin) infections? The clinical trial protocols should be less onerous and the timeline much shorter.
If they can succeed here, they might have an approved commercial product in two to three years. If so, this could generate sufficient funds to cover the further clinical development of treatments for internal viral or bacterial infections such as RECCE 327 and RECCE 529,with hopefully some left over for shareholder dividends. (Assuming they are not bought out by Big Pharma first).
Ann: HREC Approval to Start Phase I/II Burns Wound Study, page-48
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.5¢ |
Change
-0.015(2.46%) |
Mkt cap ! $121.3M | |||
| Open | High | Low | Value | Volume |
| 61.0¢ | 62.5¢ | 59.5¢ | $102.7K | 169.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28498 | 59.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 63.0¢ | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
61.5¢ |
Change
-0.015 ( 0.82 %) |
||||
| Open | High | Low | Volume | ||
| 62.0¢ | 63.0¢ | 59.5¢ | 82843 | ||
| Last updated 15.58pm 17/05/2024 ? | |||||
| RCE (ASX) Chart |